The goal of the study was to ascertain whether GI adverse events (GI AEs), such as nausea/vomiting, diarrhea, constipation, and dyspepsia (indigestion), during the dose escalation phase (baseline to week 12) and from baseline to the end of treatment, are responsible for the greater weight loss seen with semaglutide compared to other GLP-1RAs
When to contact your provider about dosing Certain situations require medical guidance rather than self-adjustment
10.1016/j.carbpol.2014.11.059 Carbohyd Polym
The clinical development program included multiple phase 1, 2, and 3 trials evaluating safety, efficacy, and optimal dosing strategies in diverse patient populations
| This weight loss drug is safe and effective | This will be the biggest blockbuster drug in history Until we have the full paper to read, its good to be skeptical here
Those who want structured nutrition, fitness, or behavior coaching wont find it here